Assessing Changes in the Gut Microbiome of Non-Gastrointestinal Disordered Subjects Before and After Oral Prebiotic Supplementation Using the SIMBA Capsule

This is a randomized, double-blind, placebo-controlled, parallel-group clinical study. The primary objective is to assess the changes in the small intestinal (SI) metagenomic profile of healthy participants without any known gastrointestinal disorders from baseline to endpoint in response to the prebiotic intervention (FiberSmart). The study population are adults (n=30) who will ingest either the FiberSmart or a matched Placebo daily for 21 days. Both products will be referred to as the Investigational Product (IP) in the study procedures section. While prebiotics are widely used for gut health, their specific impact on the small intestinal ecosystem remains largely uncharacterized compared to the large intestine. Understanding their impact on the upper GI tract can lead to new insights into their mechanisms of action. Given the critical role of the small intestine in metabolism and immunity, the study utilizes the SIMBA capsule to measure novel changes in the small intestine along with traditional measurements from stool samples.

NCT Number	NCT07525739
Lead Sponsor	Nimble Science Ltd. Collaborators: Anderson Advanced Ingredients
Conditions	Prebiotic, Metagenomic Next Generation Sequencing, Microbiome, Small Intestine
Enrollment	30 participants
Start Date	2026-07-20
Primary Completion	2026-11-20 (estimated)
Study Completion	2026-12-20 (estimated)
Updated on ClinicalTrials.gov	2026-07-10